Keenova Announces Promising New Findings on TERLIVAZ® at SHM Converge Conference Keenova Therapeutics has unveiled crucial insights into TERLIVAZ® (terlipressin) for HRS-AKI during the SHM Converge 2026, illustrating its real-world use and impact.

Keenova Announces Promising New Findings on TERLIVAZ® at SHM Converge Conference #United_States #Dublin #Terlipressin #Keenova #HRS-AKI

Mallinckrodt to Showcase Innovative Terlipressin Findings at the 2025 AASLD Annual Meeting Mallinckrodt plc will present groundbreaking results on Terlipressin for hepatorenal syndrome during the upcoming AASLD 2025 meeting in Washington, D.C.

Mallinckrodt to Showcase Innovative Terlipressin Findings at the 2025 AASLD Annual Meeting #United_States #Washington_D.C. #Mallinckrodt #Hepatorenal_Syndrome #Terlipressin

Mallinckrodt to Showcase Terlipressin Research at Kidney Week 2025 Mallinckrodt will present critical data on terlipressin during Kidney Week 2025, highlighting its effects on patients with hepatorenal syndrome-acute kidney injury.

Mallinckrodt to Showcase Terlipressin Research at Kidney Week 2025 #United_States #Houston #Mallinckrodt #CKD #Terlipressin

New Data on Terlipressin Presented at DDW 2025 | Docwire News Peter Richardson and George Wan of Mallinckrodt discussed data on terlipressin for hepatorenal syndrome–acute kidney injury (HRS-AKI) presented at Digestive Disease Week 2025.

Data presented earlier this month at #DDW2025 focused on #terlipressin for HRS-AKI. What do the new studies add to the conversation? #acutekidneyinjury #hepatorenalsyndrome #HRSAKI #nephsky #nephrology #hepatology www.docwirenews.com/post/new-dat...

✨ #PosterTour today at #EASLCongress 2025:
All our 3 Horizon2020 #LiverResearch projects in 1 session!

Topic: #Cirrhosis & #PortalHypertension
Chair: Maria Papp

💡 Big moments:

#AMMON-OHE model for post-#TIPS #encephalopathy (Rajiv Jalan)

#Terlipressin response in AKI-HRS w/ CKD (Frank Uschner)

A pleasure to share knowledge re: HRS over ⁦@CWRUdeptMED⁩ ⁦@UHhospitals⁩ grand rounds. Thanks to ⁦@CLDFoundation⁩ for terrific content and some of the updated data re: #terlipressin #livertwitter ⁦@CWRU_GI⁩ https://youtu.be/FAcCesdNN9g

“To those about to use #terlipressin, we salute you”
#terlivaz #livertwitter onlinelibrary.wiley.com/doi/10.1111/apt.17195

Link to the full @US_FDA label for #terlipressin as well as the black box warning below #LiverTwitter

www.accessdata.fda.gov/drugsatfda_docs/label/20...

Other important considerations when prescribing #terlipressin
⛔️ If experiencing hypoxia or worsening respiratory symptoms
⛔️ If ongoing coronary, peripheral, or mesenteric ischemia
If listed with #MELD>35 risk may outweigh benefit d/t risk of becoming ineligible #LiverTwitter

Highlights of #terlipressin aka #terlivaz label are it’s limitations of use:
. Cr >5 unlikely to benefit
. Volume overloaded or those with 3 or more organ failures (ACLF-3) at high risk for respiratory failure
. Do not give is spO2 is or becomes under 90% #LiverTwitter

FDA Approves Terlipressin to Improve Kidney Function in H... The drug improves kidney function in adults with hepatore...

⁦@US_FDA⁩ Approves #Terlipressin to Improve Kidney Function in Hepatorenal Syndrome (HRS-AKI) #livertwitter www.pharmacytimes.com/view/fda-approves-terlip...

The results of the CONFIRM trial testing #terlipressin for #HRS were presented at the #LiverMtg19 this week.
COI: CONFIRM investigator, consultant for Mallinckrodt #hepatorenal #AKI

@AASLDtweets #terlipressin is clearly not a silver bullet for type 1 HRS and there are definitely significant AEs to contend with. Biggest disappointment in my mind was 31% reversal rate which I thought was closer to 40-45% (but different definitions) #LiverMtg19

@AASLDtweets #terlipressin caused more abdominal pain, resp. failure and more discontinuations. 2/200 had intestinal ischemia. #LiverMtg19

@AASLDtweets dr. Wong: #terlipressin meets primary endpoint of verified type 1 HRS reversal (31% vs 15% for placebo). Less patients need dialysis after transplant compared to placebo. No impact of survival #LiverMtg19

@AASLDtweets tomorrow’s #LiverMtg19 brings a long awaited practice changing dataset to the forefront at the late breaker session: #terlipressin for type 1 HRS $MNK

in typical topline press release fashion, info is scarce but the mere fact that #terlipressin met primary endpoint is exciting. Plans to file NDA in Q1 2020. More data #livermtg2019

" #terlipressin study met its primary endpoint of verified HRS-1 reversal (p=0.012). Verified HRS-1 reversal includes three components: renal function improvement, avoidance of dialysis and short-term survival"